# Signals Article on Putative Target P35670 for Wilson Disease ATP7B
Background
The protein encoded by the putative target P35670, known as "Copper-transporting ATPase 2" (ATP7B), is essential for copper homeostasis in the human body. Mutations in the ATP7B gene lead to Wilson disease, a genetic disorder characterized by excessive accumulation of copper in tissues, resulting in hepatic, neurological, and psychiatric manifestations. Given the critical role of ATP7B in copper transport and metabolism, further investigation into its expression and regulatory mechanisms may provide valuable insights for therapeutic development in Wilson disease.Data-mining rationale
In our analysis, we cross-referenced reviewed human entries from UniProt for "Wilson disease ATP7B" against four microarray datasets available in the NCBI Gene Expression Omnibus (GEO). The candidate P35670 was identified in expression-profiling studies, yet it notably lacks any registered Phase 1 or higher clinical program. This observation suggests a potential gap in the exploration of ATP7B's role in Wilson disease, indicating that it may have been overlooked in previous research.Why prior analyses may have missed this
Many of the GEO datasets utilized in our analysis predate the implementation of modern empirical-Bayes statistical methods, such as the limma package, which allows for more robust multiple-testing corrections. Consequently, the expression data related to P35670 may not have been adequately analyzed, leading to its underappreciation in the context of Wilson disease. The absence of advanced statistical techniques could have obscured significant findings that warrant further exploration.Reasoning for further validation
To substantiate the potential role of P35670 in Wilson disease, we propose the following experimental approaches:1. **Re-analyze matched GEO datasets**: Utilize the limma package with Benjamini-Hochberg false discovery rate (FDR) correction set to < 0.05 to identify differentially expressed genes associated with Wilson disease, including P35670.
2. **Validate top differentially-expressed genes**: Conduct quantitative PCR (qPCR) in an independent cohort to confirm the expression levels of P35670 and other top candidates identified in the re-analysis.
3. **Check tissue specificity**: Utilize resources such as the Genotype-Tissue Expression (GTEx) project and the Human Protein Atlas to assess the tissue-specific expression patterns of P35670, which may provide insights into its functional relevance in hepatic and neurological tissues.
4. **Run pathway context analyses**: Employ tools like STRING and OmniPath to elucidate the potential pathways in which P35670 is involved, helping to contextualize its role in Wilson disease.
5. **Assess druggability**: If validation studies confirm the involvement of P35670 in Wilson disease, evaluate its druggability using databases such as DGIdb and ChEMBL to explore potential therapeutic interventions.
References
- UniProt: P35670, Q05516, O00244, Q8N668
- GEO Accession: GDS:200125637, GDS:200024997, GDS:200005348, GDS:2509